These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16640121)

  • 61. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.
    Young JW; Geyer MA
    J Psychopharmacol; 2015 Feb; 29(2):178-96. PubMed ID: 25516372
    [TBL] [Abstract][Full Text] [Related]  

  • 62. NIMH Drug Trials for Schizophrenia.
    Torrey EF; Yolken RH; Lamb HR
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30677268
    [No Abstract]   [Full Text] [Related]  

  • 63. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia.
    Talpos JC
    Drug Discov Today; 2017 Jul; 22(7):1017-1026. PubMed ID: 28461223
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone.
    Riedel M; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Engel RR; Müller N; Möller HJ; Spellmann I
    Hum Psychopharmacol; 2010 Mar; 25(2):116-25. PubMed ID: 20196179
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.
    Luckhoff HK; Kilian S; Olivier MR; Phahladira L; Scheffler F; du Plessis S; Chiliza B; Asmal L; Emsley R
    Metab Brain Dis; 2019 Apr; 34(2):469-476. PubMed ID: 30604027
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Perospirone normalized P300 and cognitive function in a case of early psychosis.
    Higuchi Y; Sumiyoshi T; Ito T; Suzuki M
    J Clin Psychopharmacol; 2013 Apr; 33(2):263-6. PubMed ID: 23422402
    [No Abstract]   [Full Text] [Related]  

  • 70. Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
    Croarkin PE; Daskalakis ZJ
    J Am Acad Child Adolesc Psychiatry; 2012 Sep; 51(9):949-51. PubMed ID: 22917209
    [No Abstract]   [Full Text] [Related]  

  • 71. Cognitive dysfunction in schizophrenia.
    Lublin H
    Acta Psychiatr Scand Suppl; 2001; (408):5-9. PubMed ID: 11730073
    [No Abstract]   [Full Text] [Related]  

  • 72. Can genetics inform the management of cognitive deficits in schizophrenia?
    Vyas NS; Shamsi SA; Malhotra AK; Aitchison KJ; Kumari V
    J Psychopharmacol; 2012 Mar; 26(3):334-48. PubMed ID: 22328662
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Researchers focus on recovery in schizophrenia.
    Friedrich MJ
    JAMA; 2014 Jul; 312(1):16-8. PubMed ID: 24942273
    [No Abstract]   [Full Text] [Related]  

  • 76. Targeting cognition in schizophrenia research: from etiology to treatment.
    Goldberg TE; Gomar JJ
    Am J Psychiatry; 2009 Jun; 166(6):631-4. PubMed ID: 19487396
    [No Abstract]   [Full Text] [Related]  

  • 77. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cognitive effects and antipsychotic treatment.
    Kasper S; Resinger E
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():27-38. PubMed ID: 12504070
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS; Silva SG; Perkins DO; Lieberman JA
    Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.